Aeglea BioTherapeutics may be turning a corner. The biotech has managed to sell off its rare metabolic disease asset—which the FDA denied approval for last year—to Immedica Pharma for $15 million cash and the potential to make up to $100 million in milestones.

Labcorp closed out the first half of the year with the spinoff of its clinical development business, which left the nest June 30 as a standalone, publicly traded CRO dubbed Fortrea.

Fortrea has inked a deal with Australia’s Incannex Healthcare to manage investigative new drug clinical trials for a cannabinoid-based treatment for obstructive sleep apnea.

Pfizer is reorganizing its research leadership team, assigning additional duties to Chief Scientific Officer Mikael Dolsten, M.D., PhD., while bidding farewell to Chief Development Officer William Pao, M.D., PhD., who just took on the role in February 2022.

Analysts and investors wanted the tea on the FDA review of Sage Therapeutics’ zuranolone, but Biogen CEO Chris Viehbacher wouldn’t spill it.

Medicxi has loaded up its fourth fund with $400 million, which the European life sciences firm will use to continue its mission of supporting “asset-focused” biotechs.

Suddenly, protracted soccer transfer sagas are the least of Joe Lewis’ worries. The Department of Justice has leveled a raft of accusations at the billionaire owner of a Premier League club, who stands accused of conspiring to defraud Mirati Therapeutics and insider trading in Solid Biosciences.

Teleflex is inking a $650 million deal to acquire Palette Life Sciences, the maker of urologic spacer implants and tissue bulking products.

With hopes of a merger with MEI Pharma now sunk for good, Infinity Pharmaceuticals is jettisoning three-quarters of its staff and three board members to stay afloat while it scans the horizon for another financial life raft.

Biogen’s significant internal cost-cutting efforts have not deterred an aggressive hunt for deals, but CEO Chris Viehbacher doesn’t want infatuation to cloud necessary judgment.